Akron Formulations India Profile
Key Indicators
- Authorised Capital ₹ 14.00 Cr
- Paid Up Capital ₹ 13.98 Cr
- Company Age 39 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 43.07 Cr
- Satisfied Charges ₹ 3.84 Cr
- Revenue Growth -44.56%
- Profit Growth -92.67%
- Ebitda -34.02%
- Net Worth 0.67%
- Total Assets -11.49%
About Akron Formulations India
Akron Formulations India Private Limited (AFIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 05 August 1985 and has a history of 39 years and five months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Hightech Pharmaceuticals Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 14.00 Cr and a paid-up capital of Rs 13.98 Cr.
The company currently has active open charges totaling ₹43.07 Cr. The company has closed loans amounting to ₹3.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Akron Formulations India Private Limited India is Kapil Mundhada as COMPANY SECRETARY. Satyanarayana Reddy, Kumaraswamy Maruri, and Maruri Leelavathi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24239TG1985PTC005701
-
Company No.
005701
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Aug 1985
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
What products or services does Akron Formulations India Private Limited offer?
Akron Formulations India Private Limited offers a wide range of products and services, including Pharmaceutical Services, Pharmaceutical Testing Services, Third Party Manufacturing Consultancy, Contract Manufacturing Services, Pharmaceutical Contract Manufacturing Services, Web Applications Services, Web Application Development, Health Care Service, Environment Protection & Auditing, Environmental Consultants.
Who are the key members and board of directors at Akron Formulations India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kapil Mundhada | Company Secretary | 06-Mar-2024 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyanarayana Reddy
|
Director | 27-Feb-2023 | Current |
|
Kumaraswamy Maruri
|
Director | 27-Feb-2023 | Current |
| Maruri Leelavathi | Additional Director | 14-Mar-2024 | Current |
Financial Performance of Akron Formulations India.
Akron Formulations India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 44.56% decrease. The company also saw a substantial fall in profitability, with a 92.67% decrease in profit. The company's net worth moved up by a moderate rise of 0.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akron Formulations India?
In 2023, Akron Formulations India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Akron Parentarals Private LimitedSatyanarayana Reddy and Kumaraswamy Maruri are mutual person
-
Pranaya Pharmaceuticals Private Limited
Satyanarayana Reddy and Kumaraswamy Maruri are mutual person
-
Akron Consumer Care Private LimitedSatyanarayana Reddy and Kumaraswamy Maruri are mutual person
-
Safe Pharmaceuticals Pvt Ltd
Satyanarayana Reddy and Kumaraswamy Maruri are mutual person
-
Akro Soft Solutions Private Limited
Satyanarayana Reddy is a mutual person
-
Arha Pharmaceuticals Private Limited
Kumaraswamy Maruri is a mutual person
Charges (Loans)
₹43.07 Cr
₹3.84 Cr
Charges Breakdown by Lending Institutions
- Sidbi : 21.22 Cr
- Axis Bank Limited : 12.00 Cr
- Hdfc Bank Limited : 7.00 Cr
- Small Industries Development Bank Of India : 2.85 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 May 2021 | Sidbi | ₹2.00 Cr | Open |
| 26 Nov 2020 | Sidbi | ₹2.52 Cr | Open |
| 29 Jul 2019 | Hdfc Bank Limited | ₹7.00 Cr | Open |
| 06 Feb 2019 | Sidbi | ₹8.50 M | Open |
| 19 Jan 2018 | Sidbi | ₹2.00 Cr | Open |
How Many Employees Work at Akron Formulations India?
Unlock and access historical data on people associated with Akron Formulations India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akron Formulations India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akron Formulations India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
